An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on the Incidence of Pulmonary Infection and Survival in Lung Cancer Patients
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 500
- Primary Endpoint
- The incidence of pneumonia at 12 months
Study Overview
Brief Summary
To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung cancer patients.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female patients >=18 years of age;
- •Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments;
- •Never received pneumococcal vaccine
Exclusion Criteria
- •Patients having other factors that preventing researchers from enrollment them.
Arms & Interventions
Vaccination group
Lung cancer patients receive 23-valent pneumonia vaccine
Intervention: 23-valent pneumococcal vaccine (Biological)
Outcomes
Primary Outcomes
The incidence of pneumonia at 12 months
Time Frame: 12 months
During the 12-month follow-up period, the incidence of pulmonary infection in lung cancer patients was evaluated through regular clinical examinations, imaging tests, and laboratory tests.
Incidence of pneumonia
Time Frame: 24 months
The proportion of lung cancer patients who developed pneumonia during the study period.
Secondary Outcomes
- Survival rate(5 years)
Investigators
Yalei Zhang
The First Affiliated Hospital of Guangzhou Medical University
The First Affiliated Hospital of Guangzhou Medical University